Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy

The investigators performed a two stages, parallel, randomized, double-blind, double-dummy, clinical trial in 240 AH children concomitant with perennial allergic rhinitis. In the first treatment stage, the 240 children were assigned to MF (50μg, 1 puff in each nostril every evening) or control group (normal saline) after two week's run-in period. After 6 week's treatment, the children in MF group were evaluated and grouped as responders and non-responders according to subjective symptoms and objective performance.

Responders were followed up for six months and reassessed. Non-responders underwent 2-week washout period and were randomly assigned to 4 groups receiving the following treatments: placebo, OXY (0.05%, 1 puff in each nostril every evening) or MF (50μg, 1 puff in each nostril every evening). All participants received 8 weeks' MF or its placebo plus one week's OXY or its placebo for every second week. After that, the patients were followed for six months and the evaluation was done at different time points.

Inclusion criteria

• adenoid occluding at least 75% of the nasopharynx at nasal endoscopy
• age between 5 and 11 years
• chronic obstructive nasal symptoms no less than 12 months
• moderate-to-severe AR

Exclusion criteria

• tonsillar hypertrophy
• upper respiratory infection within the last 2 weeks
• sinonasal anatomic anomalies or diseases
• craniofacial malformations
• genetic diseases (i.e., Down's syndrome)
• neurologic or cardiovascular diseases
• immunodeficiency
• history of epistaxis
• asthma
• hypersensitivity to MF or OXY
• undergoing intranasal, topical, or systemic steroid or antibiotic treatment within the past 4 weeks